{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"DOR was determined for the participants with CR or CRp in the primary analysis set, defined as the time from first achieving remission to the time when progression was diagnosed, the participant died, or the participant started receiving new antineoplastic therapy. Data from participants who do not progress were censored at the last valid assessments. Median DOR and its 95% confidence interval was determined based on the Kaplan-Meier method. Data from participants who received a transplant were censored at the time of the transplant.","groups":[{"description":"Bendamustine 120 mg/m\\^2 administered as an IV infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (Cycles 2 through 12), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.","id":"OG000","title":"Phase 2: Bendamustine 120 mg/m^2"}],"populationDescription":"No duration of remission (defined as CR or CRp) analysis was performed for participants in the primary analysis since none achieved remission.","reportingStatus":"POSTED","timeFrame":"At each treatment cycle (21 to 35 days), for a maximum of 12 cycles","title":"Duration of Response (DOR)","type":"SECONDARY"}